Cyprus
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.7 (0.67 - 0.72) | 2019 | Modelled | IHME |
0.72 (0.70 - 0.75) | 2018 | Modelled | IHME |
0.74 (0.71 - 0.76) | 2017 | Modelled | IHME |
0.74 (0.72 - 0.76) | 2016 | Modelled | IHME |
0.74 (0.72 - 0.77) | 2015 | Modelled | IHME |
0.75 (0.72 - 0.77) | 2014 | Modelled | IHME |
0.76 (0.73 - 0.78) | 2013 | Modelled | IHME |
0.77 (0.74 - 0.79) | 2012 | Modelled | IHME |
0.78 (0.75 - 0.81) | 2011 | Modelled | IHME |
0.79 (0.77 - 0.82) | 2010 | Modelled | IHME |
0.8 (0.78 - 0.83) | 2009 | Modelled | IHME |
0.82 (0.79 - 0.84) | 2008 | Modelled | IHME |
0.83 (0.81 - 0.86) | 2007 | Modelled | IHME |
0.85 (0.82 - 0.87) | 2006 | Modelled | IHME |
0.86 (0.84 - 0.89) | 2005 | Modelled | IHME |
0.88 (0.85 - 0.90) | 2004 | Modelled | IHME |
0.89 (0.87 - 0.92) | 2003 | Modelled | IHME |
0.91 (0.89 - 0.94) | 2002 | Modelled | IHME |
0.93 (0.90 - 0.96) | 2001 | Modelled | IHME |
0.95 (0.92 - 0.98) | 2000 | Modelled | IHME |
0.97 (0.94 - 1) | 1999 | Modelled | IHME |
0.99 (0.96 - 1.02) | 1998 | Modelled | IHME |
1.01 (0.98 - 1.04) | 1997 | Modelled | IHME |
1.03 (1 - 1.06) | 1996 | Modelled | IHME |
1.05 (1.02 - 1.08) | 1995 | Modelled | IHME |
1.07 (1.04 - 1.10) | 1994 | Modelled | IHME |
1.1 (1.06 - 1.13) | 1993 | Modelled | IHME |
1.12 (1.09 - 1.15) | 1992 | Modelled | IHME |
1.15 (1.11 - 1.18) | 1991 | Modelled | IHME |
1.17 (1.13 - 1.21) | 1990 | Modelled | IHME |
1.72 (1.18 - 2.49) | 2015 | Modelled | WHO |
2.69 (2.38 - 3.04) | 2013 | Modelled | Schweitzer et al, 2015 |
Showing out of
Show more
Children under-5 years
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.02 (0.01 - 0.02) | 2019 | Modelled | IHME |
0.02 (0.02 - 0.02) | 2018 | Modelled | IHME |
0.02 (0.02 - 0.02) | 2017 | Modelled | IHME |
0.02 (0.02 - 0.02) | 2016 | Modelled | IHME |
0.02 (0.01 - 0.02) | 2015 | Modelled | IHME |
0.02 (0.02 - 0.02) | 2014 | Modelled | IHME |
0.02 (0.02 - 0.03) | 2013 | Modelled | IHME |
0.02 (0.02 - 0.03) | 2012 | Modelled | IHME |
0.03 (0.02 - 0.03) | 2011 | Modelled | IHME |
0.03 (0.02 - 0.03) | 2010 | Modelled | IHME |
0.03 (0.02 - 0.04) | 2009 | Modelled | IHME |
0.03 (0.03 - 0.04) | 2008 | Modelled | IHME |
0.04 (0.03 - 0.05) | 2007 | Modelled | IHME |
0.04 (0.03 - 0.05) | 2006 | Modelled | IHME |
0.05 (0.04 - 0.05) | 2005 | Modelled | IHME |
0.05 (0.04 - 0.06) | 2004 | Modelled | IHME |
0.05 (0.04 - 0.06) | 2003 | Modelled | IHME |
0.05 (0.04 - 0.06) | 2002 | Modelled | IHME |
0.06 (0.05 - 0.07) | 2001 | Modelled | IHME |
0.06 (0.05 - 0.07) | 2000 | Modelled | IHME |
0.07 (0.06 - 0.08) | 1999 | Modelled | IHME |
0.08 (0.06 - 0.09) | 1998 | Modelled | IHME |
0.09 (0.07 - 0.11) | 1997 | Modelled | IHME |
0.1 (0.08 - 0.12) | 1996 | Modelled | IHME |
0.12 (0.09 - 0.14) | 1995 | Modelled | IHME |
0.14 (0.11 - 0.16) | 1994 | Modelled | IHME |
0.16 (0.13 - 0.19) | 1993 | Modelled | IHME |
0.19 (0.15 - 0.22) | 1992 | Modelled | IHME |
0.22 (0.18 - 0.26) | 1991 | Modelled | IHME |
0.25 (0.20 - 0.30) | 1990 | Modelled | IHME |
0.6 (0.37 - 0.98) | 2015 | Modelled | WHO |
Showing out of
Show more
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
5.6 | 2017 | Survey/reported | ECDC |
1.53 | 2016 | Survey/reported | EMCDDA |
5 | 2015 | Survey/reported | EMCDDA |
0.91 | 2014 | Survey/reported | EMCDDA |
6.09 | 2013 | Survey/reported | EMCDDA |
2.38 | 2012 | Survey/reported | EMCDDA |
0.66 | 2011 | Survey/reported | EMCDDA |
1.71 | 2010 | Survey/reported | EMCDDA |
0.87 | 2009 | Survey/reported | EMCDDA |
7.84 | 2007 | Survey/reported | EMCDDA |
2.08 | 2006 | Survey/reported | EMCDDA |
3.06 | 2004 | Survey/reported | EMCDDA |
Showing out of
Show more
Number of people living with chronic HBV
National
DownloadValue | Year | Type | Source |
---|---|---|---|
9,132 (8,826 - 9,423) | 1990 | Modelled | IHME |
9,086 (8,794 - 9,364) | 1991 | Modelled | IHME |
9,040 (8,755 - 9,297) | 1992 | Modelled | IHME |
8,992 (8,720 - 9,243) | 1993 | Modelled | IHME |
8,944 (8,664 - 9,194) | 1994 | Modelled | IHME |
8,898 (8,618 - 9,168) | 1995 | Modelled | IHME |
8,858 (8,586 - 9,108) | 1996 | Modelled | IHME |
8,822 (8,548 - 9,075) | 1997 | Modelled | IHME |
8,790 (8,517 - 9,043) | 1998 | Modelled | IHME |
8,759 (8,484 - 9,023) | 1999 | Modelled | IHME |
8,731 (8,451 - 8,998) | 2000 | Modelled | IHME |
8,705 (8,443 - 8,963) | 2001 | Modelled | IHME |
8,684 (8,428 - 8,937) | 2002 | Modelled | IHME |
8,671 (8,416 - 8,923) | 2003 | Modelled | IHME |
8,671 (8,420 - 8,928) | 2004 | Modelled | IHME |
8,685 (8,428 - 8,950) | 2005 | Modelled | IHME |
8,712 (8,456 - 8,966) | 2006 | Modelled | IHME |
8,746 (8,486 - 9,004) | 2007 | Modelled | IHME |
8,787 (8,510 - 9,051) | 2008 | Modelled | IHME |
8,835 (8,548 - 9,105) | 2009 | Modelled | IHME |
8,888 (8,584 - 9,169) | 2010 | Modelled | IHME |
8,933 (8,642 - 9,223) | 2011 | Modelled | IHME |
8,968 (8,691 - 9,256) | 2012 | Modelled | IHME |
9,005 (8,725 - 9,304) | 2013 | Modelled | IHME |
9,061 (8,773 - 9,370) | 2014 | Modelled | IHME |
9,152 (8,856 - 9,462) | 2015 | Modelled | IHME |
9,282 (8,992 - 9,564) | 2016 | Modelled | IHME |
9,403 (9,098 - 9,711) | 2017 | Modelled | IHME |
9,369 (9,068 - 9,671) | 2018 | Modelled | IHME |
9,158 (8,842 - 9,457) | 2019 | Modelled | IHME |
Showing out of
Show more
HBV-related death rate
National
DownloadValue (per 100,000) | Year | Type | Source |
---|---|---|---|
1.23 (0.92 - 1.61) | 2019 | Modelled | IHME |
1.22 (0.92 - 1.59) | 2018 | Modelled | IHME |
1.2 (0.92 - 1.56) | 2017 | Modelled | IHME |
1.2 (0.92 - 1.57) | 2016 | Modelled | IHME |
1.21 (0.93 - 1.56) | 2015 | Modelled | IHME |
1.2 (0.93 - 1.55) | 2014 | Modelled | IHME |
1.19 (0.92 - 1.54) | 2013 | Modelled | IHME |
1.18 (0.91 - 1.52) | 2012 | Modelled | IHME |
1.18 (0.92 - 1.53) | 2011 | Modelled | IHME |
1.2 (0.93 - 1.56) | 2010 | Modelled | IHME |
1.21 (0.93 - 1.58) | 2009 | Modelled | IHME |
1.22 (0.94 - 1.58) | 2008 | Modelled | IHME |
1.24 (0.96 - 1.63) | 2007 | Modelled | IHME |
1.26 (0.96 - 1.64) | 2006 | Modelled | IHME |
1.27 (0.97 - 1.67) | 2005 | Modelled | IHME |
1.28 (0.98 - 1.67) | 2004 | Modelled | IHME |
1.32 (1 - 1.73) | 2003 | Modelled | IHME |
1.38 (1.04 - 1.81) | 2002 | Modelled | IHME |
1.43 (1.08 - 1.90) | 2001 | Modelled | IHME |
1.51 (1.13 - 2.03) | 2000 | Modelled | IHME |
1.6 (1.19 - 2.16) | 1999 | Modelled | IHME |
1.7 (1.27 - 2.31) | 1998 | Modelled | IHME |
1.79 (1.33 - 2.45) | 1997 | Modelled | IHME |
1.87 (1.39 - 2.55) | 1996 | Modelled | IHME |
1.92 (1.40 - 2.67) | 1995 | Modelled | IHME |
1.93 (1.39 - 2.72) | 1994 | Modelled | IHME |
1.96 (1.39 - 2.77) | 1993 | Modelled | IHME |
1.96 (1.39 - 2.80) | 1992 | Modelled | IHME |
1.94 (1.36 - 2.75) | 1991 | Modelled | IHME |
1.92 (1.34 - 2.69) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
16 (12 - 21) | 2019 | Modelled | IHME |
16 (12 - 21) | 2018 | Modelled | IHME |
15 (12 - 20) | 2017 | Modelled | IHME |
15 (12 - 20) | 2016 | Modelled | IHME |
15 (11 - 19) | 2015 | Modelled | IHME |
15 (11 - 19) | 2014 | Modelled | IHME |
14 (11 - 18) | 2013 | Modelled | IHME |
14 (11 - 18) | 2012 | Modelled | IHME |
14 (10 - 18) | 2011 | Modelled | IHME |
13 (10 - 18) | 2010 | Modelled | IHME |
13 (10 - 17) | 2009 | Modelled | IHME |
13 (10 - 17) | 2008 | Modelled | IHME |
13 (10 - 17) | 2007 | Modelled | IHME |
13 (10 - 17) | 2006 | Modelled | IHME |
13 (10 - 17) | 2005 | Modelled | IHME |
13 (10 - 17) | 2004 | Modelled | IHME |
13 (10 - 17) | 2003 | Modelled | IHME |
13 (10 - 17) | 2002 | Modelled | IHME |
13 (10 - 18) | 2001 | Modelled | IHME |
14 (10 - 19) | 2000 | Modelled | IHME |
14 (11 - 20) | 1999 | Modelled | IHME |
15 (11 - 21) | 1998 | Modelled | IHME |
16 (12 - 21) | 1997 | Modelled | IHME |
16 (12 - 22) | 1996 | Modelled | IHME |
16 (12 - 23) | 1995 | Modelled | IHME |
16 (12 - 23) | 1994 | Modelled | IHME |
16 (11 - 23) | 1993 | Modelled | IHME |
16 (11 - 23) | 1992 | Modelled | IHME |
15 (11 - 22) | 1991 | Modelled | IHME |
15 (10 - 21) | 1990 | Modelled | IHME |
48 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
11 (8 - 17) | 2019 | Modelled | IHME |
11 (8 - 16) | 2018 | Modelled | IHME |
11 (8 - 17) | 2017 | Modelled | IHME |
11 (8 - 16) | 2016 | Modelled | IHME |
11 (8 - 16) | 2015 | Modelled | IHME |
11 (8 - 16) | 2014 | Modelled | IHME |
12 (8 - 17) | 2013 | Modelled | IHME |
12 (8 - 17) | 2012 | Modelled | IHME |
12 (8 - 17) | 2011 | Modelled | IHME |
12 (8 - 17) | 2010 | Modelled | IHME |
12 (8 - 17) | 2009 | Modelled | IHME |
12 (8 - 17) | 2008 | Modelled | IHME |
12 (8 - 17) | 2007 | Modelled | IHME |
12 (8 - 17) | 2006 | Modelled | IHME |
12 (8 - 18) | 2005 | Modelled | IHME |
12 (9 - 18) | 2004 | Modelled | IHME |
13 (9 - 18) | 2003 | Modelled | IHME |
13 (9 - 18) | 2002 | Modelled | IHME |
13 (9 - 19) | 2001 | Modelled | IHME |
13 (9 - 19) | 2000 | Modelled | IHME |
13 (9 - 19) | 1999 | Modelled | IHME |
14 (10 - 19) | 1998 | Modelled | IHME |
14 (10 - 20) | 1997 | Modelled | IHME |
14 (10 - 20) | 1996 | Modelled | IHME |
14 (10 - 20) | 1995 | Modelled | IHME |
14 (10 - 20) | 1994 | Modelled | IHME |
14 (10 - 20) | 1993 | Modelled | IHME |
14 (10 - 20) | 1992 | Modelled | IHME |
14 (10 - 20) | 1991 | Modelled | IHME |
14 (10 - 20) | 1990 | Modelled | IHME |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
1 | 2017 | Survey/reported | EMCDDA, 2019 |
0 (0 - 0) | 2015 | Survey/reported | EMCDDA, 2017 |
1 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
18 | 2017 | Survey/reported | EMCDDA, 2019 |
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
No policy
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
No policy
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.64 (0.52 - 0.79) | 2019 | Modelled | IHME |
0.64 (0.52 - 0.79) | 2018 | Modelled | IHME |
0.64 (0.52 - 0.79) | 2017 | Modelled | IHME |
0.62 (0.51 - 0.77) | 2016 | Modelled | IHME |
0.61 (0.50 - 0.75) | 2015 | Modelled | IHME |
0.61 (0.50 - 0.75) | 2014 | Modelled | IHME |
0.61 (0.50 - 0.75) | 2013 | Modelled | IHME |
0.61 (0.50 - 0.75) | 2012 | Modelled | IHME |
0.61 (0.49 - 0.75) | 2011 | Modelled | IHME |
0.61 (0.49 - 0.74) | 2010 | Modelled | IHME |
0.59 (0.48 - 0.73) | 2009 | Modelled | IHME |
0.56 (0.46 - 0.69) | 2008 | Modelled | IHME |
0.53 (0.44 - 0.64) | 2007 | Modelled | IHME |
0.5 (0.42 - 0.61) | 2006 | Modelled | IHME |
0.49 (0.40 - 0.59) | 2005 | Modelled | IHME |
0.49 (0.40 - 0.59) | 2004 | Modelled | IHME |
0.49 (0.40 - 0.59) | 2003 | Modelled | IHME |
0.49 (0.40 - 0.58) | 2002 | Modelled | IHME |
0.48 (0.40 - 0.58) | 2001 | Modelled | IHME |
0.48 (0.40 - 0.58) | 2000 | Modelled | IHME |
0.48 (0.40 - 0.59) | 1999 | Modelled | IHME |
0.48 (0.39 - 0.58) | 1998 | Modelled | IHME |
0.48 (0.39 - 0.58) | 1997 | Modelled | IHME |
0.48 (0.39 - 0.58) | 1996 | Modelled | IHME |
0.48 (0.39 - 0.58) | 1995 | Modelled | IHME |
0.49 (0.40 - 0.59) | 1994 | Modelled | IHME |
0.51 (0.41 - 0.61) | 1993 | Modelled | IHME |
0.53 (0.43 - 0.65) | 1992 | Modelled | IHME |
0.57 (0.46 - 0.70) | 1991 | Modelled | IHME |
0.6 (0.49 - 0.75) | 1990 | Modelled | IHME |
Showing out of
Show more
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
43.28 | 2016 | Survey/reported | EMCDDA |
44.2 | 2015 | Survey/reported | EMCDDA |
43.11 | 2014 | Survey/reported | EMCDDA |
47.56 | 2013 | Survey/reported | EMCDDA |
55.42 | 2012 | Survey/reported | EMCDDA |
52.63 | 2011 | Survey/reported | EMCDDA |
51.28 | 2010 | Survey/reported | EMCDDA |
46.55 | 2009 | Survey/reported | EMCDDA |
29.21 | 2008 | Survey/reported | EMCDDA |
34.31 | 2007 | Survey/reported | EMCDDA |
29.59 | 2006 | Survey/reported | EMCDDA |
50 | 2008 | Survey/reported | EMCDDA; Demetriou V. L., Van de Vijver D. A., Hezka J., Georgiades N., Savvopoulou N., Charilaou C. C., Argyriou A., Pavlou T., Platritis K., Veresies K., Kostrikis L. , 2009 |
9.1 | 2004 | Survey/reported | EMCDDA |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.26 (0.21 - 0.36) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
0.6 (0.50 - 1.90) | 2014 | Survey/reported | Gower et al, 2014 |
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
49.7 (44.40 - 55) | 2014 | Modelled | Degenhardt L et al, 2017 |
47.6 (36.40 - 58.90) | 2013 | Survey/reported | EMCDDA |
56.6 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
Number of people living with chronic HCV (RNA+/cAg)
National
DownloadValue | Year | Type | Source |
---|---|---|---|
4,690 (3,799 - 5,836) | 1990 | Modelled | IHME |
4,485 (3,646 - 5,553) | 1991 | Modelled | IHME |
4,296 (3,489 - 5,212) | 1992 | Modelled | IHME |
4,145 (3,378 - 5,033) | 1993 | Modelled | IHME |
4,059 (3,323 - 4,938) | 1994 | Modelled | IHME |
4,067 (3,303 - 4,948) | 1995 | Modelled | IHME |
4,134 (3,363 - 5,011) | 1996 | Modelled | IHME |
4,206 (3,434 - 5,091) | 1997 | Modelled | IHME |
4,281 (3,502 - 5,188) | 1998 | Modelled | IHME |
4,359 (3,575 - 5,289) | 1999 | Modelled | IHME |
4,440 (3,644 - 5,353) | 2000 | Modelled | IHME |
4,524 (3,714 - 5,456) | 2001 | Modelled | IHME |
4,615 (3,785 - 5,556) | 2002 | Modelled | IHME |
4,714 (3,871 - 5,698) | 2003 | Modelled | IHME |
4,823 (3,957 - 5,838) | 2004 | Modelled | IHME |
4,943 (4,054 - 5,990) | 2005 | Modelled | IHME |
5,183 (4,285 - 6,267) | 2006 | Modelled | IHME |
5,589 (4,614 - 6,765) | 2007 | Modelled | IHME |
6,065 (4,977 - 7,436) | 2008 | Modelled | IHME |
6,504 (5,313 - 7,984) | 2009 | Modelled | IHME |
6,788 (5,515 - 8,351) | 2010 | Modelled | IHME |
6,949 (5,652 - 8,580) | 2011 | Modelled | IHME |
7,098 (5,802 - 8,750) | 2012 | Modelled | IHME |
7,241 (5,896 - 8,906) | 2013 | Modelled | IHME |
7,386 (6,022 - 9,086) | 2014 | Modelled | IHME |
7,538 (6,122 - 9,274) | 2015 | Modelled | IHME |
7,816 (6,384 - 9,663) | 2016 | Modelled | IHME |
8,119 (6,596 - 10,046) | 2017 | Modelled | IHME |
8,315 (6,780 - 10,191) | 2018 | Modelled | IHME |
8,468 (6,863 - 10,372) | 2019 | Modelled | IHME |
Showing out of
Show more
Women of childbearing age (15–49 years)
DownloadValue | Year | Type | Source |
---|---|---|---|
790 (640 - 1,100) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
DownloadValue (Deaths per 100,000) | Year | Type | Source |
---|---|---|---|
3.79 (3 - 4.72) | 2019 | Modelled | IHME |
3.73 (2.93 - 4.62) | 2018 | Modelled | IHME |
3.67 (2.91 - 4.53) | 2017 | Modelled | IHME |
3.67 (2.92 - 4.54) | 2016 | Modelled | IHME |
3.67 (2.95 - 4.56) | 2015 | Modelled | IHME |
3.62 (2.90 - 4.50) | 2014 | Modelled | IHME |
3.58 (2.87 - 4.41) | 2013 | Modelled | IHME |
3.52 (2.82 - 4.31) | 2012 | Modelled | IHME |
3.5 (2.82 - 4.32) | 2011 | Modelled | IHME |
3.5 (2.80 - 4.34) | 2010 | Modelled | IHME |
3.46 (2.76 - 4.32) | 2009 | Modelled | IHME |
3.45 (2.75 - 4.33) | 2008 | Modelled | IHME |
3.45 (2.73 - 4.35) | 2007 | Modelled | IHME |
3.43 (2.69 - 4.31) | 2006 | Modelled | IHME |
3.38 (2.67 - 4.26) | 2005 | Modelled | IHME |
3.31 (2.63 - 4.20) | 2004 | Modelled | IHME |
3.3 (2.59 - 4.22) | 2003 | Modelled | IHME |
3.33 (2.62 - 4.27) | 2002 | Modelled | IHME |
3.34 (2.62 - 4.29) | 2001 | Modelled | IHME |
3.38 (2.62 - 4.40) | 2000 | Modelled | IHME |
3.42 (2.63 - 4.45) | 1999 | Modelled | IHME |
3.42 (2.61 - 4.46) | 1998 | Modelled | IHME |
3.4 (2.58 - 4.45) | 1997 | Modelled | IHME |
3.41 (2.56 - 4.46) | 1996 | Modelled | IHME |
3.43 (2.58 - 4.51) | 1995 | Modelled | IHME |
3.46 (2.56 - 4.53) | 1994 | Modelled | IHME |
3.52 (2.57 - 4.67) | 1993 | Modelled | IHME |
3.53 (2.54 - 4.72) | 1992 | Modelled | IHME |
3.49 (2.49 - 4.66) | 1991 | Modelled | IHME |
3.45 (2.46 - 4.58) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
DownloadValue | Year | Type | Source |
---|---|---|---|
50 (39 - 62) | 2019 | Modelled | IHME |
48 (38 - 60) | 2018 | Modelled | IHME |
47 (37 - 58) | 2017 | Modelled | IHME |
46 (37 - 57) | 2016 | Modelled | IHME |
45 (36 - 56) | 2015 | Modelled | IHME |
44 (35 - 54) | 2014 | Modelled | IHME |
43 (34 - 53) | 2013 | Modelled | IHME |
41 (33 - 50) | 2012 | Modelled | IHME |
40 (32 - 49) | 2011 | Modelled | IHME |
39 (31 - 49) | 2010 | Modelled | IHME |
38 (30 - 47) | 2009 | Modelled | IHME |
37 (30 - 47) | 2008 | Modelled | IHME |
36 (29 - 46) | 2007 | Modelled | IHME |
35 (28 - 44) | 2006 | Modelled | IHME |
34 (27 - 43) | 2005 | Modelled | IHME |
33 (26 - 42) | 2004 | Modelled | IHME |
32 (25 - 41) | 2003 | Modelled | IHME |
32 (25 - 41) | 2002 | Modelled | IHME |
31 (24 - 40) | 2001 | Modelled | IHME |
31 (24 - 40) | 2000 | Modelled | IHME |
31 (24 - 40) | 1999 | Modelled | IHME |
30 (23 - 40) | 1998 | Modelled | IHME |
30 (23 - 39) | 1997 | Modelled | IHME |
29 (22 - 38) | 1996 | Modelled | IHME |
29 (22 - 38) | 1995 | Modelled | IHME |
29 (21 - 38) | 1994 | Modelled | IHME |
29 (21 - 38) | 1993 | Modelled | IHME |
29 (20 - 38) | 1992 | Modelled | IHME |
28 (20 - 37) | 1991 | Modelled | IHME |
27 (19 - 36) | 1990 | Modelled | IHME |
38 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
40 (30 - 50) | 2019 | Modelled | IHME |
40 (30 - 50) | 2018 | Modelled | IHME |
40 (30 - 50) | 2017 | Modelled | IHME |
40 (30 - 50) | 2016 | Modelled | IHME |
40 (30 - 50) | 2015 | Modelled | IHME |
40 (29 - 50) | 2014 | Modelled | IHME |
39 (29 - 50) | 2013 | Modelled | IHME |
39 (29 - 49) | 2012 | Modelled | IHME |
39 (29 - 49) | 2011 | Modelled | IHME |
39 (29 - 48) | 2010 | Modelled | IHME |
38 (29 - 48) | 2009 | Modelled | IHME |
38 (29 - 48) | 2008 | Modelled | IHME |
38 (28 - 48) | 2007 | Modelled | IHME |
38 (28 - 48) | 2006 | Modelled | IHME |
37 (27 - 47) | 2005 | Modelled | IHME |
37 (27 - 47) | 2004 | Modelled | IHME |
37 (27 - 47) | 2003 | Modelled | IHME |
37 (27 - 47) | 2002 | Modelled | IHME |
37 (27 - 47) | 2001 | Modelled | IHME |
37 (27 - 47) | 2000 | Modelled | IHME |
37 (27 - 47) | 1999 | Modelled | IHME |
37 (27 - 47) | 1998 | Modelled | IHME |
37 (27 - 47) | 1997 | Modelled | IHME |
37 (27 - 48) | 1996 | Modelled | IHME |
37 (28 - 48) | 1995 | Modelled | IHME |
38 (28 - 48) | 1994 | Modelled | IHME |
38 (28 - 48) | 1993 | Modelled | IHME |
38 (28 - 48) | 1992 | Modelled | IHME |
38 (28 - 48) | 1991 | Modelled | IHME |
38 (28 - 48) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
DownloadValue | Year | Type | Source |
---|---|---|---|
1 | 2017 | Survey/reported | EMCDDA, 2019 |
0 (0 - 0) | 2015 | Survey/reported | EMCDDA, 2017 |
1 | 2017 | Survey/reported | ECDC |
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
DownloadValue (%) | Year | Type | Source |
---|---|---|---|
18 | 2017 | Survey/reported | EMCDDA, 2019 |
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
No policy
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
No policy
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
Overview
HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030
Prevalence (national)
Modelled
Survey/surveillance
No data available
Hepatitis related deaths (national)
Prevalence < 5
HBV
0.02
(%)
2019, latest modelled
(0.01 - 0.02(%))
IHME
Prevalence PWID
HCV
56.60
(%)
2017, survey/surveillance
ECDC
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines